EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 226 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR New on NCI Websites for October 2018 October 30, 2018 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan July 21, 2022 Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... May 19, 2021 Load more HOT NEWS Scientists Focus on Fusion Proteins in Childhood Cancers Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas Saying YES: Inspiring a Diverse Generation of Cancer Scientists Autumn and Letting Go
